Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
OwnerMarvin B. Bacaner, Maurice M. Kreevoyinventors
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel pharmaceutical combinations including compositions and kits comprising bretylium as the active ingredient, as well as methods for preventing and/or treating conditions related to the cardiovascular system using such novel pharmaceutical combinations.
Claims185
A pharmaceutical combination useful for preventing and/or treating a cardiovascular condition, the pharmaceutical combination comprising:
- a bretylium cation or a source of a bretylium cation;
- an acetylsalicylate anion or a source of an acetylsalicylate anion;
- and
- a β-receptor blocker or a source of a β-receptor blocker,
- said acetylsalicylate anion comprising a compound of the structure:
- 7
- wherein:
- R17 is independently hydrocarbyl or substituted hydrocarbyl;
- R18 is hydrogen, hydrocarbyl or substituted hydrocarbyl;
- and
- said bretylium cation or said source of a bretylium cation, said acetylsalicylate anion or source of an acetylsalicylate anion, and said β-receptor blocker or said source of a β-receptor blocker together are present in said pharmaceutical combination in a therapeutically effective amount.
A pharmaceutical combination useful for preventing and/or treating a cardiovascular condition, said pharmaceutical combination comprising:
- a bretylium cation or a source of a bretylium cation;
- acetylsalicylic acid or an alkali metal salt of acetylsalicylic acid;
- and
- a β-receptor blocker or a source of a β-receptor blocker, wherein:
- said pharmaceutical combination is suitable for oral ingestion;
- and
- said bretylium cation or said source of a bretylium cation, said acetylsalicylic acid or said alkali metal salt of acetylsalicylic acid, and said β-receptor blocker or said source of a β-receptor blocker together are present in said pharmaceutical composition in a therapeutically effective amount.
A pharmaceutical composition comprising from about 10% to about 40% by weight bretylium cation, from about 5% to about 40% by weight acetylsalicylate anion, and from about 0.1% to about 1.0% by weight β-receptor blocker.
A pharmaceutical composition comprising a bretylium cation, an acetylsalicylate anion, a β-receptor blocker and a neutralizing agent.
A method for treating and/or preventing shock, the method comprising administering a pharmaceutical combination comprising a bretylium cation or a source of a bretylium cation, a facilitating anion or a source of a facilitating anion, and an anti-hypotensive agent and/or a β-receptor blocker or a source of an anti-hypotensive agent and/or a β-receptor blocker to a human or animal patient in need thereof, wherein:
- said facilitating anion is less hydrophilic than a tosylate anion;
- and
- said bretylium cation or said source of a bretylium cation, said facilitating anion or said source of a facilitating anion, and said anti-hypotensive agent and/or said β-receptor blocker or said source of an anti-hypotensive agent and/or a β-receptor blocker together are present in said pharmaceutical combination in a therapeutically effective amount.
Dependencies are inferred from the claim text.